Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study - Concepedia

Concepedia

Publication | Closed Access

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

572

Citations

21

References

2013

Year

Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová,

Arthritis & Rheumatism

Abstract

Data from this 12-month interim analysis demonstrate that tofacitinib inhibits progression of structural damage and improves disease activity in patients with RA who are receiving MTX.

References

	Year	Citations

Page 1